Medicus Pharma (NASDAQ:MDCX - Free Report) had its price target raised by D. Boral Capital from $14.00 to $27.00 in a research report sent to investors on Monday,Benzinga reports. D. Boral Capital currently has a buy rating on the stock.
A number of other research analysts have also recently issued reports on MDCX. D Boral Capital raised shares of Medicus Pharma to a "strong-buy" rating in a report on Monday, April 14th. Maxim Group increased their price target on shares of Medicus Pharma from $10.00 to $20.00 and gave the company a "buy" rating in a research report on Thursday, May 8th.
Read Our Latest Analysis on MDCX
Medicus Pharma Trading Up 13.1%
Medicus Pharma stock traded up $0.78 during mid-day trading on Monday, reaching $6.73. The company had a trading volume of 310,901 shares, compared to its average volume of 65,954. Medicus Pharma has a 1 year low of $1.80 and a 1 year high of $7.00. The business's 50-day simple moving average is $3.94.
Medicus Pharma (NASDAQ:MDCX - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.19). On average, sell-side analysts forecast that Medicus Pharma will post -1.14 EPS for the current fiscal year.
Institutional Trading of Medicus Pharma
Several large investors have recently modified their holdings of the business. Armistice Capital LLC acquired a new stake in shares of Medicus Pharma in the first quarter valued at approximately $4,710,000. Private Advisor Group LLC acquired a new stake in Medicus Pharma during the first quarter worth approximately $211,000. Finally, Interchange Capital Partners LLC boosted its position in Medicus Pharma by 14.0% during the first quarter. Interchange Capital Partners LLC now owns 1,661,871 shares of the company's stock worth $6,182,000 after acquiring an additional 204,706 shares during the last quarter.
Medicus Pharma Company Profile
(
Get Free Report)
Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.
Read More
Before you consider Medicus Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medicus Pharma wasn't on the list.
While Medicus Pharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
